Literature DB >> 8912533

Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.

U Stein1, W Walther, R H Shoemaker.   

Abstract

Reversal of multidrug resistance (MDR) may offer a means of increasing the effectiveness of tumour chemotherapy. A variety of recent evidence indicates that cytokines may be particularly useful in this endeavour. To investigate the molecular mechanism by which cytokines may sensitise multidrug-resistant colon carcinoma cells, HCT15 and HCT116, to treatment with MDR-related drugs, we evaluated the effects of the human cytokines tumour necrosis factor alpha (TNF alpha), interleukin 2 (IL-2) and interferon gamma (IFN gamma) on mdr1 gene expression at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level with monoclonal antibodies by immuno flow cytometry. P-glycoprotein function was examined after accumulation of the fluorescent drug, doxorubicin, by flow cytometry. Chemosensitivity to doxorubicin and vincristine was analysed using the XTT assay. All three cytokines were found to modulate the MDR characteristics on mdr1 expression levels, P-glycoprotein function and measured chemosensitivity to MDR-associated anti-cancer drugs. This cytokine-induced reversal of MDR was strongly time dependent, with maximal effects after 48 and 72 h of cytokine treatment. If similar modulation of MDR phenotype can be obtained in in vivo models, it may be possible to verify the time course for modulation by cytokine treatment and to design appropriate clinical trials of this strategy for MDR reversal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912533      PMCID: PMC2074774          DOI: 10.1038/bjc.1996.553

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

Review 1.  Function and regulation of the human multidrug resistance gene.

Authors:  K V Chin; I Pastan; M M Gottesman
Journal:  Adv Cancer Res       Date:  1993       Impact factor: 6.242

2.  Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications.

Authors:  M Valenti; G Cimoli; S Parodi; G L Mariani; M Venturini; P Conte; P Russo
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 3.  Immunoregulation by cytokines.

Authors:  G Kroemer; I Moreno de Alborán; J A Gonzalo; C Martínez
Journal:  Crit Rev Immunol       Date:  1993       Impact factor: 2.214

Review 4.  The reversal of multidrug resistance in cancer (review).

Authors:  J A Kellen
Journal:  Anticancer Res       Date:  1993 Jul-Aug       Impact factor: 2.480

Review 5.  P-glycoproteins: mediators of multidrug resistance.

Authors:  U A Germann; I Pastan; M M Gottesman
Journal:  Semin Cell Biol       Date:  1993-02

Review 6.  Tumor necrosis factor activities and cancer therapy--a perspective.

Authors:  R S Sidhu; A P Bollon
Journal:  Pharmacol Ther       Date:  1993-01       Impact factor: 12.310

Review 7.  Molecular targets in oncology: implications of the multidrug resistance gene.

Authors:  B L Lum; M P Gosland; S Kaubisch; B I Sikic
Journal:  Pharmacotherapy       Date:  1993 Mar-Apr       Impact factor: 4.705

Review 8.  Clinical trials of agents that reverse multidrug resistance. A literature review.

Authors:  M Raderer; W Scheithauer
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

9.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

Authors:  M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper
Journal:  Int J Cancer       Date:  1996-01-17       Impact factor: 7.396

10.  Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3).

Authors:  E Monti; E G Mimnaugh; B K Sinha
Journal:  Biochem Pharmacol       Date:  1993-05-25       Impact factor: 5.858

View more
  10 in total

1.  Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.

Authors:  N W Lutz; S E Franks; M H Frank; S Pomer; W E Hull
Journal:  MAGMA       Date:  2005-06-23       Impact factor: 2.310

2.  Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells.

Authors:  Mohammad M Al-Bataineh; Deon van der Merwe; Bruce D Schultz; Ronette Gehring
Journal:  Biopharm Drug Dispos       Date:  2010-10-22       Impact factor: 1.627

Review 3.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

4.  Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia.

Authors:  Chuanhui Yu; George Argyropoulos; Yan Zhang; Abba J Kastin; Hung Hsuchou; Weihong Pan
Journal:  Cell Physiol Biochem       Date:  2008-12-09

5.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 6.  Management of osteosarcoma.

Authors:  Jeremy Whelan; Beatrice Seddon; Martha Perisoglou
Journal:  Curr Treat Options Oncol       Date:  2006-11

7.  Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Authors:  J Li; L Z Xu; K L He; W J Guo; Y H Zheng; P Xia; Y Chen
Journal:  Breast Cancer Res       Date:  2001-04-02       Impact factor: 6.466

8.  Streptococcus agalactiae disrupts P-glycoprotein function in brain endothelial cells.

Authors:  Brandon J Kim; Maura A McDonagh; Liwen Deng; Benjamin D Gastfriend; Alexandra Schubert-Unkmeir; Kelly S Doran; Eric V Shusta
Journal:  Fluids Barriers CNS       Date:  2019-08-22

9.  Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF.

Authors:  Christelle Monville; Christiane Fages; Anne-Marie Feyens; Veronique D'Hondt; Catherine Guillet; Ann Vernallis; Hugues Gascan; Marc Peschanski
Journal:  BMC Cell Biol       Date:  2002-07-31       Impact factor: 4.241

10.  Study of in vitro and in vivo effects of 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells.

Authors:  J J Wang; Y F Chang; Y T Chern; C W Chi
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.